Analyst Price Targets — SABS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 24, 2026 11:23 am | Eliana Merle | Barclays | $13.00 | $3.87 | TheFly | SAB Biotherapeutics initiated with an Overweight at Barclays |
| May 20, 2026 9:00 am | — | Jefferies | $11.00 | $3.55 | TheFly | SAB Biotherapeutics initiated with a Buy at Jefferies |
| May 12, 2026 3:58 pm | Emily Bodnar | H.C. Wainwright | $10.00 | $3.65 | TheFly | SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright |
| January 7, 2026 6:01 am | Michael Yee | UBS | $7.00 | $3.62 | StreetInsider | UBS Starts SAB Biotherapeutics (SABS) at Buy |
| September 17, 2025 10:58 am | — | Leerink Partners | $7.00 | $2.58 | TheFly | SAB Biotherapeutics initiated with an Outperform at Leerink |
| June 7, 2024 3:45 am | Kumaraguru Raja | Loop Capital Markets | $8.00 | $2.84 | StreetInsider | Brookline Capital Markets Starts SAB Biotherapeutics (SABS) at Buy |
| April 2, 2024 6:44 am | Edward White | H.C. Wainwright | $6.00 | $4.29 | StreetInsider | SAB Biotherapeutics (SABS) PT Lowered to $6 at H.C. Wainwright following Q4 report |
| August 11, 2022 7:41 am | — | Chardan Capital | $3.00 | $1.12 | Benzinga | Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $3 |
Latest News for SABS
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in upcoming investor conferences in September:
AWM Investment Company Inc. purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ: SABS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 375,000 shares of the company's stock, valued at approximately $1,462,000. AWM Investment Company Inc. owned 0.41% of SAB
SAB Biotherapeutics NASDAQ: SABS said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expected in the second half of 2027.
Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027 Breakthrough T1D awarded a grant to PRISE ‑ hATG study of SAB ‑ 142 in patients with Stage 3 type 1 diabetes who are 100 days to 2 years from diagnosis Operational runway through 2028 to support SAFEGUARD…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SABS.
U.S. House Trading
No House trades found for SABS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.